77 results about "Vaccine delivery" patented technology

The invention discloses an alternate medicine discharging method, belongs to the technical field of automatic distribution of vaccines, and solves the problem that in the prior art, the vaccination station is low in vaccination and emergence efficiency. The alternate medicine discharging method comprises the specific steps that the AGV medicine conveying trolley conveys vaccines into the drawer frame of the inoculation table, the vaccine guiding device is switched between the two electric drawers, the AGV medicine conveying trolley drives away from the drawer frame and conveys the vaccines into the electric drawers, and the two electric drawers are opened alternately. By arranging the AGV medicine delivery trolley, the vaccine pouring device, the drawer switching device and the vaccine guiding device, vaccines can be alternately put into the two electric drawers, and the electric drawers are vertically arranged, so that the vaccination efficiency can be greatly improved, and meanwhile, the leg space of medical staff cannot be affected.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

The invention relates to RNA constructs encoding (i) at least one therapeutic biomolecule; and (ii) at least one innate inhibitor protein (IIP). The constructs are RNA replicons and saRNA molecules, and the invention includes genetic constructs or vectors encoding such RNA replicons. The invention extends to the use of such RNA constructs and replicons in therapy, for example in treating diseases and / or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

The invention discloses a lipid nanoparticle-platelet conjugate as well as a preparation method and application thereof. The conjugate is formed by coupling lipid nanoparticles and platelets through a covalent modification method, a non-covalent modification method or a genetic engineering method, and the lipid nanoparticles can be loaded with nucleic acid, small molecules, protein / polypeptide drugs or CRISPR / Cas system components. The lipid nanoparticles have the drug carrying function of lipid nanoparticles and the natural spleen targeting characteristic of platelets, and the drug uptake rate and delivery efficiency of immune cells can be improved. The preparation method adopts manual mixing, ethanol injection or a microfluidic method, is simple, convenient and efficient, can be completed within several minutes, and does not damage platelets. According to the conjugate, the drug loading type and the coupling mode can be adjusted according to different diseases, the limitation of a single drug carrier is broken through, and the conjugate can adapt to various scenes such as tumor treatment and vaccine delivery and meet the personalized treatment requirement.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

A method for inducing an immune response in an individual to treat or prevent a disease or condition is provided, the method comprising administering a vaccine comprising lipid nanoparticles encapsulating nucleic acids encoding antigen proteins, peptides, or fragments thereof, a neutral lipid content of 30% to 70% molar ratio, sterols or derivatives thereof, and 5 to 50% molar ratio of ionizable cationic amino lipids, and a hydrophilic polymer-lipid conjugate present at a lipid content of 0% to 5% molar ratio, wherein administration of the lipid nanoparticles results in an immune response in an individual against the antigen protein, peptide, or fragment thereof expressed by mRNA, wherein each % molar ratio of lipid content relative to the total lipid content of the lipid nanoparticles is measured. This disclosure also provides vaccine compositions and the use of such compositions in inducing an immune response in an individual.

The invention belongs to the technical field of biological medicine, and particularly relates to an RNA balling modification method. According to the invention, a novel imidazole derivative 1-azio-15-(1H-midazol-1-yl)-3, 6, 9, 12-tetroxapetadecan-15-one is synthesized, a brand new sRNA synthesis modification system is developed on the basis of the compound, the compound is modified by a RNA ribose two-position hydroxyl group, the hydrolysis resistance of RNA is improved, the modified RNA forms spherical particles by virtue of a microfluidic system, and the hydrolysis resistance of the RNA is improved. Meanwhile, the spherical structure is stabilized through connection of the lipid compound, so that the diameter of the synthesized spherical RNA is remarkably reduced compared with that before balling, the stability is greatly improved, a solution is provided for the defects of poor RNA delivery stability and dependence on a carrier in the prior art, and a new strategy is provided for RNA vaccine delivery.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immune modulator) and / or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and / or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.

The invention discloses a preparation and delivery strategy of a dendritic cell targeting vaccine. The vaccine delivery platform comprises: a) an antibody having a DC targeting function, which is selected from a targeting antibody of CD205; and b) a carrier antigen which is obtained by fusion expression of the antibody affinity molecule integrated with the non-natural amino acid and the antigen epitope or the antigen epitope splicing protein. According to the present invention, the CD205 antibody is adopted, the antigen epitope fusion protein containing the antibody affinity molecule is prepared through the UAA integration technology, and the fusion protein can be subjected to proximity induction coupling with the CD205 antibody through the UAA affinity molecule so as to achieve the efficient self-assembly of the CD205 and the antigen epitope; the vaccine delivery platform provided by the invention can realize accurate, efficient and switchable antigen delivery, provides a simple, convenient and flexible DC vaccine design strategy suitable for different antigens, and has a wide immunotherapy application prospect.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The present disclosure provides a microemulsion-based vaccine delivery system, and further provides a preparation method and an application thereof. Using the microemulsion absorbing a series of metal ion compounds, and adding an antigen in a preparation process, antigen entrapment can be realized and a stable vaccine preparation is obtained. The prepared vaccine can effectively be taken up by an antigen-presenting cell and effectively delivered to lymph nodes to induce an antigen-specific immune response, and the same has a wide application prospect.

The invention provides a codon sequence quality evaluation method for integrating protein structure characteristics. The core idea is that the advantages and disadvantages of the codon sequence are not measured only by the coincidence degree of the codon sequence and the average preference of a host, and whether the codon sequence serves a final functional target, namely, the codon sequence is efficiently and correctly translated and folded into a protein with a specific structure, is considered. According to the invention, protein structure characteristics and codon use preference are creatively integrated, and a novel function-oriented codon sequence evaluation index is established. Experimental results prove that the index can effectively predict expression efficiency of codon optimization or design sequences, and a new quantification tool is provided for rational design of optimal codon sequences of heterologous proteins and fully artificially designed proteins. The method is suitable for codon sequence evaluation of various expression hosts, has wide practicability, and provides a new technical tool for enzyme regulation in the fields of recombinant protein production, nucleic acid drug / vaccine delivery, transgenosis and synthetic biology.

The invention relates to a gas-driven double-cavity microneedle as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, preparing a needle tip solution, filling a microneedle mold with the needle tip solution, vacuumizing and drying to obtain a blank cavity microneedle with a first-stage cavity and a second-stage cavity; s2, sequentially filling the I-stage cavity with medicine powder and filling the II-stage cavity with aerogenesis powder through a vacuum method or a centrifugal method, adhering and fixing a medical adhesive tape to the surface of the blank cavity microneedle, and demolding to obtain the gas-driven double-cavity microneedle, the invention also discloses application of the gas-driven double-cavity microneedle prepared by the method in preparation of a drug delivery system, a vaccine delivery system, a medical beauty product, a diagnosis monitoring marker and a gene therapy vector system. The invention has the effects of supporting orthogonal regulation and control of gas production kinetics and drug release behavior, being capable of carrying out customized compatibility aiming at different disease treatment scenes, and having broad-spectrum applicability and clinical transformation potential.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The present application relates to a kind of preparation method and application of HPV recombinant protein therapeutic vaccine, belong to biological medicine technical field, the preparation method of the HPV recombinant protein therapeutic vaccine described includes: a plurality of complex lipid nanoparticles prepared by lipid are simultaneously wrapped and delivered HPV16HPV E6E7 recombinant protein antigen and nucleic acid TLR agonist adjuvant molecule.This application is beneficial to the recombinant protein therapeutic vaccine prepared to induce strong T cell immune response to HPV16E6E7 antigen, kill the cervical cancer cell infected by HPV.In addition, unlike the lipid nanoparticle (LNP) of mRNA vaccine delivery, there is no cation or ionizable lipid in the formula, significantly higher than mRNA vaccine in safety, with greater advantage than mRNA therapeutic vaccine, and low toxicity and side effects, vaccine effect is stable.

The application belongs to the technical field of biological medicine, and specifically discloses preparation and application of self-assembled glycopeptide nanoparticles for mRNA vaccine delivery, wherein the nanoparticles are formed by self-assembly of a glycopeptide carrier, mRNA and manganese ions. In the nanoparticle preparation process, the manganese ions are adsorbed onto tryptophan and histidine through metal chelation, and play an adjuvant role in activating the cGAS-STING pathway after administration. The nanoparticles can effectively adsorb mRNA, can stably exist for 4 weeks at 4 DEG C, protect mRNA from enzymatic degradation, promote intracellular mRNA internalization and lysosome escape, effectively transfect eGFP-mRNA and Fluc-mRNA in DC2.4 and BMDC cells, and effectively target mRNA delivery to lymph nodes, activate the cGAS-STING pathway, effectively activate the specific immune system in a B16F10-OVA prevention model, delay tumor growth, and prolong the survival cycle of mice.

The present invention discloses a calcium-doped manganese carbonate multimodal vaccine delivery system, its preparation method, and application. The vaccine delivery system is obtained by loading listeriolysin O with calcium-doped manganese carbonate microspheres, wherein the calcium-doped manganese carbonate microspheres are prepared by the following method: (1) stirring and mixing a CaCl2 aqueous solution and a MnCl2 aqueous solution, and then adding sodium polystyrene sulfonate to obtain a mixed solution of CaCl2 and MnCl2 containing PSS; (2) adding sodium polystyrene sulfonate to a Na2CO3 aqueous solution, mixing uniformly, and then adding the mixed solution dropwise to the mixed solution of CaCl2 and MnCl2 containing PSS, stirring and reacting, to obtain calcium-doped manganese carbonate microspheres. The multimodal tumor vaccine delivery system constructed by the present invention can conceal the toxicity of LLO and improve cellular immune response, and has important application value in the field of tumor vaccines.

This invention relates to RNA constructs encoding (i) at least one therapeutic biomolecule; and (ii) at least one innate inhibitor protein (IIP). The constructs are RNA replicons and saRNA molecules, and the invention comprises genetic constructs or vectors encoding such RNA replicons. The invention extends to the use of such RNA constructs and replicons in therapy, such as in treating diseases and / or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, as well as methods and uses thereof.

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

The invention provides a Hunipah virus mRNA vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The mRNA vaccine provided by the invention comprises mRNA attached to glycoprotein of a full-length Hendea virus and an mRNA vaccine delivery system, and serological analysis and a Nipah virus-Malaysia strain and Hendea virus challenge protection experiment prove that the vaccine provided by the invention can generate a very good immune protection effect only by immunizing two doses; the mRNA vaccine has effectiveness on a Nipah virus-Malaysia strain and a Hendea virus at the same time, can protect a subject from lethal infection of the Nipah virus-Malaysia strain and the Hendea virus, and is good in broad spectrum.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

The invention relates to a method of preparing a microneedle array, comprising the steps of dissolving a water-soluble copolymer, comprising maleic anhydride and isobutylene monomers, in an aqueous solvent to obtain an aqueous solution, adding a ceramic material to said aqueous solution to obtain an aqueous ceramic slurry for gel casting, adding at least a portion of said aqueous ceramic slurry to a mould to obtain a layer of aqueous ceramic slurry in said mould, degassing said layer of aqueous ceramic slurry to obtain a degassed layer of aqueous ceramic slurry in said mould, gelling said degassed layer of aqueous ceramic slurry to remove said aqueous solvent from said aqueous ceramic slurry and removing said mould to obtain a gelled tape, drying said gelled tape to obtain a green tape, sintering said green tape to obtain said microneedle array. Further, the invention provides for a green tape, comprising a base plate and a set of microneedles integrated with said base plate, a microneedle array, comprising a base plate and a set of microneedles integrated with said base plate, a system for enabling transport of a substance through a material barrier, and a use of a microneedle array for intradermal drug or vaccine delivery, diagnostics, cosmeceuticals,, sensing of biomarkers found in the skin and monitoring of physiological conditions of the body.

The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immune modulator) and / or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and / or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.

The invention discloses a photo-thermal self-healing drug-loaded microneedle patch and a preparation method and application thereof, and belongs to the technical field of transdermal drug delivery. Firstly, an initial needle body is prepared from a synthetic high polymer material, photo-thermal nano-particles and a first solvent, after the initial needle body and a substrate prepared from a curable material are combined and cured, low-temperature treatment is conducted, and a drug-loaded microneedle patch is obtained; the preparation method comprises the following steps: preparing a first solvent and a second solvent, demolding to obtain a preformed micro-needle patch, immersing the preformed micro-needle patch into the second solvent, carrying out solvent replacement on the first solvent and the second solvent, drying to obtain a porous micro-needle patch, dropwise adding a vaccine solution or a drug solution to the surface of a needle body of the porous micro-needle patch, and enabling a vaccine or a drug to enter the needle body in a vacuum-assisted manner to obtain the porous micro-needle patch. And after drying, applying near-infrared light to irradiate, and accelerating the closing of the holes of the needle body based on a photothermal effect to obtain the photothermal self-healing drug-loaded microneedle patch. The invention provides an efficient, stable and controllable novel delivery platform for the fields of vaccine delivery, immunotherapy, transdermal delivery of biological agents and the like.

The present application relates to the technical field of nano-vaccine, and particularly relates to fluorinated or alkylated polyaspartic acid, a preparation method thereof and application thereof in vaccine delivery. The fluorinated or alkylated polyaspartic acid has a structure shown in formula I. The fluorinated or alkylated N-substituted polyaspartic acid provided by the present application has excellent self-assembly capacity, and has good biocompatibility and low cytotoxicity. In the preparation of a nano-vaccine, the loaded antigen can be co-assembled into nanoparticles with the fluorinated or alkylated polyaspartic acid through hydrophobic interaction. In addition, the fluorinated or alkylated N-substituted polyaspartic acid retains the high cell uptake and endosome escape level of the N-substituted polyaspartic acid itself. Therefore, the fluorinated or alkylated N-substituted polyaspartic acid can enhance antigen uptake and promote cross-presentation.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

1. The name of this design product: vaccine conveyor belt. 2. Purpose of this design product: used for vaccine delivery. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture. 5. The bottom surface of this design product is difficult to see or cannot be seen during use, so the top view is omitted.

The present disclosure provides a protein-based nanoparticle made of a protein and an amine for the delivery of a nucleic acid molecule, such as an mRNA vaccine, to a cell. The present disclosure further provides systems and methods for producing such protein-based nanoparticle including a nucleic acid molecule, and methods of delivering the nucleic acid molecule to a cell, and treating a subject with the compositions as disclosure herein.

The present disclosure provides oral antigenic compositions comprising a recombinant Spirulina comprising at least one exogenous antigenic epitope. Oral antigenic compositions of the present disclosure can be used as vaccines. Oral antigenic compositions of the present disclosure can be used to induce a protective immune response to infectious microorganism, tumor antigens, or self-antigens.